Literature DB >> 20579276

Patient preferences and assessment of likely adherence to hepatitis C virus treatment.

A Brett Hauber1, A F Mohamed, C Beam, J Medjedovic, J Mauskopf.   

Abstract

To estimate patient preferences for attributes of hepatitis C virus (HCV) treatment and patients' assessment of the likely effect of treatment attributes on treatment adherence, HCV patients ≥18 years old completed an online survey that included nine 2-alternative choice questions. Each choice question was defined by the probability of sustained viral response (Efficacy), injection frequency (Frequency), duration of flu-like symptoms after every injection (Flu), injection device (Device), average number of days of work missed each week (Lost Work Days), probability of reversible hair thinning while on treatment (Alopecia) and probability of developing clinical depression while on treatment (Depression). We estimated a mean relative importance weight for each attribute. Patients also answered three rating questions to assess the extent to which treatment attributes might affect adherence. Hundred and fifty patients completed the survey. Efficacy was the most important attribute with a mean relative importance weight of 10 [95% CI: 7.9-12.1]. The remaining attributes were ranked in order of importance as follows: Depression (4.4 [95% CI: 3.6-5.1]), Flu Days(Frequency×Flu) (3.7 [95% CI: 2.2-5.3]), Lost Work Days (2.9 [95% CI: 2.3-3.5]), Alopecia (1.3 [95% CI: 0.7-1.9]) and Device (1.2 [95% CI: 0.4-2.0]). Patients with prior treatment experience were less likely to indicate that treatment attributes would affect adherence. Patients also indicated that increases in the number of flu days would increase the likelihood of nonadherence to treatment. Sustained viral response is the most important treatment attribute to patients but treatment side effects might affect treatment adherence.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20579276     DOI: 10.1111/j.1365-2893.2010.01343.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  17 in total

Review 1.  A descriptive review on methods to prioritize outcomes in a health care context.

Authors:  Inger M Janssen; Ansgar Gerhardus; Milly A Schröer-Günther; Fülöp Scheibler
Journal:  Health Expect       Date:  2014-08-25       Impact factor: 3.377

Review 2.  Risk as an attribute in discrete choice experiments: a systematic review of the literature.

Authors:  Mark Harrison; Dan Rigby; Caroline Vass; Terry Flynn; Jordan Louviere; Katherine Payne
Journal:  Patient       Date:  2014       Impact factor: 3.883

Review 3.  Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.

Authors:  Richard De Abreu Lourenco; Marion Haas; Jane Hall; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

Review 4.  Understanding Patient Preferences in Medication Nonadherence: A Review of Stated Preference Data.

Authors:  Tracey-Lea Laba; Beverley Essue; Merel Kimman; Stephen Jan
Journal:  Patient       Date:  2015-10       Impact factor: 3.883

5.  Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences.

Authors:  Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Mallory O Johnson; Tessa M Napoles; Elise D Riley
Journal:  AIDS Care       Date:  2019-03-04

6.  Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

Authors:  Axel C Mühlbacher; John F P Bridges; Susanne Bethge; Ch-Markos Dintsios; Anja Schwalm; Andreas Gerber-Grote; Matthias Nübling
Journal:  Eur J Health Econ       Date:  2016-02-04

7.  Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).

Authors:  Maria Patrizia Carrieri; Camelia Protopopescu; Zobair Younossi; Antoine Vilotitch; Hélène Fontaine; Ventzislava Petrov-Sanchez; Fabienne Marcellin; Fabrice Carrat; Christophe Hézode; Marc Bourlière
Journal:  Patient       Date:  2017-10       Impact factor: 3.481

8.  Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST).

Authors:  A Brett Hauber; Juan Marcos Gonzalez; John Coombs; Andres Sirulnik; David Palacios; Norman Scherzer
Journal:  Patient Prefer Adherence       Date:  2011-06-24       Impact factor: 2.711

9.  Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection.

Authors:  Teresa L Kauf; Ateesha F Mohamed; A Brett Hauber; Derek Fetzer; Atiya Ahmad
Journal:  Patient       Date:  2012       Impact factor: 3.883

10.  Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes.

Authors:  A Brett Hauber; Steven Han; Jui-Chen Yang; Ira Gantz; Kaan Tunceli; Juan Marcos Gonzalez; Kimberly Brodovicz; Charles M Alexander; Michael Davies; Kristy Iglay; Qiaoyi Zhang; Larry Radican
Journal:  Patient Prefer Adherence       Date:  2013-09-18       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.